Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

920 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modelling Decline in Cognition to Decline in Function in Alzheimer's Disease.
Karcher H, Savelieva M, Qi L, Hummel N, Caputo A, Risson V, Capkun G, Alzheimer's Disease Neuroimaging Initiative. Karcher H, et al. Among authors: caputo a. Curr Alzheimer Res. 2020;17(7):635-657. doi: 10.2174/1567205017666201008105429. Curr Alzheimer Res. 2020. PMID: 33032508
The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease.
Langbaum JB, Ellison NN, Caputo A, Thomas RG, Langlois C, Riviere ME, Graf A, Lopez Lopez C, Reiman EM, Tariot PN, Hendrix SB. Langbaum JB, et al. Among authors: caputo a. Alzheimers Res Ther. 2020 May 27;12(1):66. doi: 10.1186/s13195-020-00633-2. Alzheimers Res Ther. 2020. PMID: 32460855 Free PMC article.
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer's disease.
Caputo A, Racine A, Paule I, Tariot PN, Langbaum JB, Coello N, Riviere ME, Ryan JM, Lopez CL, Graf A; National Alzheimer’s Coordinating Center; Alzheimer’s Disease Neuroimaging Initiative. Caputo A, et al. Alzheimers Res Ther. 2023 Mar 6;15(1):45. doi: 10.1186/s13195-023-01183-z. Alzheimers Res Ther. 2023. PMID: 36879340 Free PMC article.
The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease.
Lopez Lopez C, Tariot PN, Caputo A, Langbaum JB, Liu F, Riviere ME, Langlois C, Rouzade-Dominguez ML, Zalesak M, Hendrix S, Thomas RG, Viglietta V, Lenz R, Ryan JM, Graf A, Reiman EM. Lopez Lopez C, et al. Among authors: caputo a. Alzheimers Dement (N Y). 2019 Jun 12;5:216-227. doi: 10.1016/j.trci.2019.02.005. eCollection 2019. Alzheimers Dement (N Y). 2019. PMID: 31211217 Free PMC article. Review.
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study.
Vandenberghe R, Riviere ME, Caputo A, Sovago J, Maguire RP, Farlow M, Marotta G, Sanchez-Valle R, Scheltens P, Ryan JM, Graf A. Vandenberghe R, et al. Among authors: caputo a. Alzheimers Dement (N Y). 2016 Dec 23;3(1):10-22. doi: 10.1016/j.trci.2016.12.003. eCollection 2017 Jan. Alzheimers Dement (N Y). 2016. PMID: 29067316 Free PMC article.
Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes.
Riviere ME, Langbaum JB, Turner RS, Rinne JO, Sui Y, Cazorla P, Ricart J, Meneses K, Caputo A, Tariot PN, Reiman EM, Graf A. Riviere ME, et al. Among authors: caputo a. Alzheimers Dement. 2024 Mar;20(3):1839-1850. doi: 10.1002/alz.13532. Epub 2023 Dec 25. Alzheimers Dement. 2024. PMID: 38145469 Free PMC article.
Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.
Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, Kressig RW, Downs P, Caputo A, Strohmaier C. Cummings J, et al. Among authors: caputo a. Dement Geriatr Cogn Disord. 2012;33(5):341-53. doi: 10.1159/000340056. Epub 2012 Jul 11. Dement Geriatr Cogn Disord. 2012. PMID: 22796905 Free article. Clinical Trial.
920 results